Literature DB >> 19082467

The expression of CRM1 is associated with prognosis in human osteosarcoma.

Yang Yao1, Yang Dong, Feng Lin, Hui Zhao, Zan Shen, Ping Chen, Yuan-Jue Sun, Li-Na Tang, Shui-Er Zheng.   

Abstract

The nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) is involved in the nuclear export of proteins and messenger RNAs and, thus, mediates the subcellular distribution of important molecules. Osteosarcoma is a ubiquitous and highly aggressive malignant bone tumor. The expression of CRM1 protein in human osteosarcoma has not been reported to date. We investigated the expression of CRM1 in 57 human osteosarcoma and 5 normal cartilage tissues. Western blot investigation revealed expression of CRM1 was significantly increased in osteosarcoma compared with normal tissues. High expression of CRM1 was significantly associated with increased serum level of alkaline phosphatase (ALP, P=0.001) but did not associate with that of lactate dehydrogenase (LDH, P=0.06). In univariate analysis, a significant association between CRM1 expression and tumor size (P=0.014) as well as histological grade (P=0.003) was observed, while high CRM1 expression was not correlated with the other clinicopathological parameters. In Kaplan-Meier survival analysis, high CRM1 expression was a significant prognostic indicator for progression-free survival (P=0.016) as well as overall survival (P=0.008). Multivariate analysis demonstrated that expression of CRM1 was an independent prognostic parameter for longer overall survival (95% CI, 1.27-5.39). Additional prospective studies are required to investigate the prognostic role of high expression of CRM1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19082467

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  85 in total

1.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

2.  XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Authors:  Takahito Miyake; Sunila Pradeep; Sherry Y Wu; Rajesha Rupaimoole; Behrouz Zand; Yunfei Wen; Kshipra M Gharpure; Archana S Nagaraja; Wei Hu; Min Soon Cho; Heather J Dalton; Rebecca A Previs; Morgan L Taylor; Takeshi Hisamatsu; Yu Kang; Tao Liu; Sharon Shacham; Dilara McCauley; David H Hawke; John E Wiktorowicz; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.

Authors:  Fang Zhou; Wensheng Qiu; Ruyong Yao; Jinyu Xiang; Xiaoxiao Sun; Shihai Liu; Jing Lv; Lu Yue
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

4.  Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.

Authors:  Paul M Tyler; Mariah M Servos; Romy C de Vries; Boris Klebanov; Trinayan Kashyap; Sharon Sacham; Yosef Landesman; Michael Dougan; Stephanie K Dougan
Journal:  Mol Cancer Ther       Date:  2017-02-01       Impact factor: 6.261

5.  Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Authors:  Sabiha Kazim; Mokenge P Malafa; Domenico Coppola; Kazim Husain; Sherma Zibadi; Trinayan Kashyap; Marsha Crochiere; Yosef Landesman; Tami Rashal; Daniel M Sullivan; Amit Mahipal
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

Review 6.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

7.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

8.  CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Authors:  Y-T Tai; Y Landesman; C Acharya; Y Calle; M Y Zhong; M Cea; D Tannenbaum; A Cagnetta; M Reagan; A A Munshi; W Senapedis; J R Saint-Martin; T Kashyap; S Shacham; M Kauffman; Y Gu; L Wu; I Ghobrial; F Zhan; A L Kung; S A Schey; P Richardson; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2013-04-16       Impact factor: 11.528

9.  Prognostic value of Twist and E-cadherin in patients with osteosarcoma.

Authors:  Ke Yin; Qiande Liao; Hongbo He; Da Zhong
Journal:  Med Oncol       Date:  2012-07-31       Impact factor: 3.064

10.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.